Suppr超能文献

低分子量壳聚糖对小鼠感染的抗疟疗效。

Antimalarial efficacy of low molecular weight chitosan against infection in mice.

作者信息

Teimouri Aref, Haghi Afsane Motevalli, Nateghpour Mehdi, Farivar Leila, Hanifian Haleh, Mavi Sara Ayazian, Zare Roghayeh

机构信息

Department of Medical Parasitology and Mycology, School of Public Health, Tehran, Iran.

Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

出版信息

J Vector Borne Dis. 2016 Oct-Dec;53(4):312-316.

Abstract

BACKGROUND & OBJECTIVES: Despite continuous global attempts to fight parasitic infections, malaria still remains one of the major human life threatening diseases. Difficulty of producing efficient antimalaria vaccines and increasing drug-resistant strains, highlight the urgent need to search for a new alternative antimalaria drug. The aim of this study was to find a new agent against malaria parasite with maximum efficacy and minimum range of side-effects. For this, the antiplasmodial activity of commercial chitosan, a natural carbohydrate polymer, was evaluated on Plasmodium berghei via in vivo experiments. This is the first report that to highlight antimalarial effects of low molecular weight chitosan against P. berghei in vivo.

METHODS

Low molecular weight chitosan with 95% degree of deacetylation was melted in normal saline with 1% (w/v) acetic acid for preparing 10, 20, 40 and 80 mg/kg concentrations of chitosan, which were then examined for their antimalarial efficacy in P. berghei infected mice.

RESULTS

The study showed that differrent concentrations of chitosan exhibited significant antimalarial effect (p= 0.002) when compared with the control group. Also, analysis of mice survival time showed significant differences between 20 and 80 mg/kg concentrations of used chitosan in comparison to negative control group.

INTERPRETATION & CONCLUSION: The results of this study showed that the chitosan has potent antimalarial activity and could be suggested as an alternative antimalarial drug component.

摘要

背景与目的

尽管全球一直在不断努力对抗寄生虫感染,但疟疾仍然是威胁人类生命的主要疾病之一。高效抗疟疾疫苗生产困难以及耐药菌株不断增加,凸显了寻找新型抗疟疾药物的迫切需求。本研究的目的是找到一种针对疟原虫的新型药物,其疗效最佳且副作用范围最小。为此,通过体内实验评估了天然碳水化合物聚合物商用壳聚糖对伯氏疟原虫的抗疟活性。这是首篇强调低分子量壳聚糖对伯氏疟原虫体内抗疟作用的报告。

方法

将脱乙酰度为95%的低分子量壳聚糖溶于含1%(w/v)乙酸的生理盐水中,制备浓度为10、20、40和80mg/kg的壳聚糖,然后在感染伯氏疟原虫的小鼠中检测其抗疟效果。

结果

研究表明,与对照组相比,不同浓度的壳聚糖均表现出显著的抗疟作用(p = 0.002)。此外,对小鼠存活时间的分析显示,与阴性对照组相比,20和80mg/kg浓度的壳聚糖之间存在显著差异。

解读与结论

本研究结果表明,壳聚糖具有强大的抗疟活性,可作为抗疟疾药物成分的替代品。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验